
The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year.

The two PCSK9 inhibitors have fallen far short of expectations. Inclisiran, which works by RNA inference, only needs to be injected twice a year.

DMARDs and the JAK Inhibitors have improved RA treatment. But not many new drugs are in the offing at the moment.

The first FDA-approved product for NASH on the horizon.

Find out what’s in the drug pipeline for autoimmune disease.

A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.

Published: July 29th 2016 | Updated:

Published: December 27th 2016 | Updated:

Published: February 5th 2020 | Updated:

Published: March 5th 2020 | Updated:

Published: June 22nd 2020 | Updated: